The clinical-stage biopharmaceutical company which is dedicated to programmed cellular immunotherapies development for immune disorders and cancers said that the Investigational New Drug application for off-the-shelf natural killer (NK) cell cancer immunotherapy, FT538 was given FDA nod.
With this, the company has decided to start its clinical investigation for the drug's three once-weekly doses as acute myeloid leukemia (AML) monotherapy, along with a combination of daratumumab, a CD38-directed monoclonal antibody therapy directed towards multiple myeloma treatment.
Please email or contact us for any edits or errors relating to this stock market news.
If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market, and other Stock Market news.
We will get back to you within 24 hours.
The post Stocks Trading Above 52 Week Low and Below 52 Week High: $IOVA $CRBP $FATE appeared first on The Market Signals .
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.